Provenge (sipuleucel-T) / Bausch Health |
ProvONE, NCT06134232: Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T |
|
|
| Not yet recruiting | 3 | 400 | NA | Sipuleucel-T Injection | Dendreon | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/31 | 06/32 | | |
ProVent, NCT03686683: Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer |
|
|
| Active, not recruiting | 3 | 450 | US | sipuleucel-T | Dendreon, PRA Health Sciences | Adenocarcinoma of the Prostate | 12/23 | 02/24 | | |
NCT05751941: Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer |
|
|
| Recruiting | 2 | 26 | US | Abiraterone, Enzalutamide, Xtandi, Apalutamide, Sipuleucel-T, Provenge | H. Lee Moffitt Cancer Center and Research Institute, Dendreon | Prostate Cancer, Metastatic Prostate Cancer | 10/25 | 10/25 | | |
NCT06100705: Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC |
|
|
| Recruiting | 2 | 26 | US | Testosterone Cypionate, DEPO-Testosterone, Sipuleucel-T, Provenge | Yale University, Dendreon | Metastatic Castration-resistant Prostate Cancer | 12/27 | 03/28 | | |
| Recruiting | 1 | 12 | US | Sipuleucel-T, PROVENGE | University of Oklahoma, Dendreon | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 11/24 | 11/24 | | |